FDA Advisory Panel Recommends BPC-157 and 5 Other Peptides for the 503A Compounding List
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six peptides — including BPC-157, TB-500, and KPV — for the Section 503A Bulk Drug Substances List. Here's what actually happened, and what it does and doesn't mean.
The short version: this is not FDA drug approval. It's a non-binding committee recommendation about a separate, narrower question — whether compounding pharmacies may legally use these substances — and it changes nothing about any compound's legal status today.
What Happened
The FDA's Pharmacy Compounding Advisory Committee met on July 23–24, 2026, to review seven peptides nominated for inclusion on the Section 503A Bulk Drug Substances List — the list that governs which bulk substances compounding pharmacies may legally use to prepare custom medications. The committee reviewed BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and DSIP (reviewed under the name emideltide).
Six of the seven received narrow, non-binding recommendations for inclusion: BPC-157 and KPV each passed 8–6 with one abstention, MOTS-c passed 7–5 with two abstentions, and TB-500, Semax, and Epitalon were also recommended. DSIP was the only compound voted down, 7–6 with one abstention.
What the Vote Actually Means
This is the part most coverage glosses over: FDA career staff's own written briefing concluded that none of the seven peptides met the agency's four-part evidentiary standard for 503A inclusion. The committee voted against that staff recommendation for six of the seven compounds — an unusual outcome, and one reason this vote drew wider attention than a typical PCAC meeting.
It's also important to be precise about what "the 503A list" governs. Section 503A of the Food, Drug & Cosmetic Act covers whether a licensed compounding pharmacy may use a bulk substance to prepare a custom, patient-specific preparation. It is a completely separate legal question from FDA drug approval — the process that determines whether a manufactured product can be marketed as a safe and effective drug for a specific indication. None of the six recommended peptides have been evaluated or approved by the FDA as a drug. Being recommended for the compounding list is not the same as being approved.
The Seven Peptides Reviewed
| Compound | Committee Vote | Outcome |
|---|---|---|
| BPC-157 | 8–6 (1 abstention) | Recommended |
| KPV | 8–6 (1 abstention) | Recommended |
| TB-500 | Recommended | Recommended |
| MOTS-c | 7–5 (2 abstentions) | Recommended |
| Semax | Recommended | Recommended |
| Epitalon | Recommended | Recommended |
| DSIP (as emideltide) | 7–6 (1 abstention) | Not recommended |
All six of KYIN Peptides' catalogue compounds in this review (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) received a recommendation; DSIP, which KYIN references but does not stock, did not.
What Happens Next
A PCAC recommendation is advisory only. The Secretary of Health and Human Services must still act on it, and any actual change to the 503A Bulks List requires formal notice-and-comment rulemaking — a process the FDA has indicated typically takes 8 to 12 months or longer, sometimes considerably longer. Until that rulemaking is complete, the legal status of these compounds for compounding purposes is unchanged from before the vote.
Why This Doesn't Change Anything About Our Products Today
KYIN Peptides sells every product strictly as labeled — a laboratory research chemical, not for human, animal, diagnostic, or therapeutic use. Nothing in this vote changes that framing, and nothing in this vote constitutes FDA approval of any compound as a drug. We're publishing this update because it's a genuinely significant regulatory development worth tracking accurately, not because it changes how these products are sold. See our Peptide Comparison Chart for how this fits alongside each compound's FDA and human-trial status, and our Malaysia & Singapore legal-status overview for the regulatory framework that actually governs these products where KYIN operates — this vote is a U.S. FDA process and doesn't directly affect Malaysian or Singaporean law.
Sources
FDA compounding update questions
Does this mean BPC-157 is now FDA-approved?
No. This vote has nothing to do with FDA drug approval. It concerns a separate, narrower question: whether compounding pharmacies may legally use these substances under Section 503A of the FD&C Act. No compound discussed here has been evaluated or approved by the FDA as a safe and effective drug for any indication.
Did the FDA's own scientists support this recommendation?
No. FDA career staff's written review concluded that none of the seven peptides reviewed met the agency's four-part evidentiary standard for inclusion on the 503A Bulks List. The advisory committee voted against that staff recommendation for six of the seven — an unusual outcome for this kind of review.
Has anything about these compounds' legal status actually changed?
Not yet, and not automatically. PCAC votes are recommendations, not decisions. The Secretary of Health and Human Services must still act on the recommendation, and any actual addition to the 503A Bulks List requires formal notice-and-comment rulemaking, which the FDA itself has said typically takes 8 to 12 months or longer.
Which peptides were reviewed, and what were the outcomes?
Seven peptides were reviewed: BPC-157 (recommended, 8–6), KPV (recommended, 8–6), TB-500 (recommended), MOTS-c (recommended, 7–5), Semax (recommended), and Epitalon (recommended) — all six against FDA staff's own recommendation. DSIP (reviewed as emideltide) was the only one voted down, 7–6.
See how this fits the full picture
Compare FDA and human-trial status for every compound we reference, or browse the catalogue.